Clinical trials · Washington, D.C., DC
Lung cancer clinical trials in Washington, D.C.
We’re tracking 236 recruiting lung cancer studies with a site in or near Washington, D.C. — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06287775RecruitingPhase 1/Phase 2
Testing a new drug combo for small cell lung cancer
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Washington D.C., District of ColumbiaAges 18–80 - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04499053RecruitingPhase 2
Durvalumab and tremelimumab with chemotherapy for advanced lung cancer in HIV
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06712316RecruitingPhase 2/Phase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Arlington, VirginiaAges 18 years+ - NCT07222566RecruitingPhase 3
New drug plus chemotherapy for advanced lung cancer
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
Silver Spring, MarylandAges 18 years+ - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
Silver Spring, MarylandAges 18 years+ - NCT07218146RecruitingPhase 3
Study of ZL-1310 vs Standard Care for Relapsed Small Cell Lung Cancer
This trial tests a new drug, ZL-1310, against standard treatments for people with small cell lung cancer that has returned after initial therapy. The goal is to see if ZL-1310 works better than other options.
Silver Spring, MarylandAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
Silver Spring, MarylandAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Silver Spring, MarylandAges Any age - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Silver Spring, MarylandAges 18 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Bethesda, MarylandAges 18 years+ - NCT02682667Recruiting
Providing blood samples for cancer immunotherapy research
This study collects and stores blood/tissue samples (called biospecimens) to support immunotherapy research at the cancer center. If you may qualify, your samples help researchers test new immune-based cancer treatments.
Bethesda, MarylandAges 18–120 - NCT05600933Enrolling by invitation
Providing tumor samples to find new treatment targets
This study collects tumor tissue and related blood tests from people who already need a biopsy or surgery as part of their usual care. Researchers use the samples to learn what drives the tumor and how the tumor environment may affect treatment, which could help develop future therapies.
Bethesda, MarylandAges 18 years+ - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT00242723Recruiting
Looking at cell changes in lung, esophagus, and chest cancers
This study collects blood, urine, and tissue samples from people with lung, esophageal, or other chest cancers to look at cell changes. It does not test a new treatment—instead, it aims to better understand these cancers through research.
Bethesda, MarylandAges 2–120 - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Bethesda, MarylandAges 18 years+
Hear when a new Lung cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Lung cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting lung cancer studies listed above.
- National Institutes of Health Clinical Center · 6 studies
- Virginia Cancer Specialists · 4 studies
- Georgetown Lombardi Comprehensive Cancer Center · 2 studies
- Johns Hopkins University · 2 studies
- Maryland Oncology Hematology, P.A. · 2 studies
- MedStar Georgetown University Hospital · 2 studies
- MedStar Washington Hospital Center · 2 studies
- NEXT Virginia · 2 studies
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lung cancer studies in District of Columbia.
Common questions
- Are there lung cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 236 recruiting lung cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.